GlassScriptPhysician profile
Lee R Copeland
NPI 1619958501
$4,840.69
in general payments reported to CMS, 2019-2025
49 companies · $1,138 in 2025
The $1,138 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,239 · 2020: $450 · 2021: $651 · 2022: $553 · 2023: $354 · 2024: $457 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,948.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $745.70 | 2019-2025 | Qulipta |
| Amgen INC. | $416.37 | 2019-2024 | Otezla, Repatha |
| Novo Nordisk INC | $373.30 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $307.09 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $263.11 | 2019-2024 | Jardiance, Mounjaro |
| Pfizer INC. | $261.13 | 2019-2025 | |
| Abbott Laboratories | $203.26 | 2019-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.35 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $167.85 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $146.40 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $145.86 | 2019-2025 | Airsupra |
| Janssen Pharmaceuticals, INC | $138.88 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $118.80 | 2019-2025 | Rexulti |
| Sk Life Science, INC. | $97.05 | 2022 | |
| Viiv Healthcare Company | $89.18 | 2025 | Apretude, Dovato, Cabenuva |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Copeland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.